NCT04906694 - Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

January 13, 2022

Study Completion Date

January 13, 2022

Conditions

Covid19

Interventions

BIOLOGICAL

COVI-DROPS

COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2

DRUG

Placebo

Diluent solution

Trial Locations (18)

24501

Infectious Diseases Associates of Central Virginia, Lynchburg

30269

Randomize Now, Peachtree City

32256

Clinical Neuroscience dba CNS Healthcare, Jacksonville

32789

Clinical Site Partners, Inc, Winter Park

32801

Clinical Neuroscience Solutions Healthcare, Orlando

33165

Med-Care Research, Miami

33614

Precision Research Center, Tampa

37421

WR-ClinSearch, Chattanooga

43215

Remington Davis, Columbus

48126

Revival Research Institute, Dearborn

68114

Quality Clinical Research, Omaha

75154

Epic Research, Red Oak

76051

Precision Comprehensive Clinical Research Solutions, Grapevine

77062

Centex Studies Inc. Houston, Houston

77584

LinQ, Pearland

78628

Advanced Medical Trials, Georgetown

80907

Future Innovative Treatments, LLC, Colorado Springs

97030

Cyn3rgy Research, Gresham

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY